Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...

Genentech has executed another round of layoffs, eliminating 87 positions at its headquarters in South San Francisco. | Genentech has executed another round of layoffs, eliminating 87 positions at its ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Oregon Governor Tina Kotek tours Genentech's Hillsboro facility, highlighting innovation and local talent development.

The job cuts include technical and scientific roles and follow multiple rounds of layoffs over the past 18 months.

Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination ...

We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...

In the same vein as weather forecast models that predict developing storms, researchers now have developed a method to ...

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.